Todd C Davis bought $1.0M of LGND
Chief Executive Officer at LIGAND PHARMACEUTICALS INC. 9,510 shares at an average of $105.20, traded May 9, 2025, filed May 13, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.0M at market
- +3Relative to holdingsHoldings up 6%
- +14Price context8% above the 52-week low; 20% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001011-25-000029, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 9, 2025 | POpen-market purchase Common Stock | +1,680 | $104.57 | $176k | 153,404 | May 13, 2025 |
| May 9, 2025 | POpen-market purchase Common Stock | +2,307 | $104.53 | $241k | 155,711 | May 13, 2025 |
| May 9, 2025 | POpen-market purchase Common Stock | +5,523 | $105.67 | $584k | 161,234 | May 13, 2025 |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.5M 5,000 shares | -14% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 32Weak | LIGAND PHARMACEUTICALS INC | John L Lamattina director | $434k 2,161 shares | -7% | |
| 35Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $208k 1,000 shares | -3% | |
| 28Weak | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $688k 3,057 shares | -13% | |
| 37Weak | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $2.8M 13,423 shares | -38% | |
| 25Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.0M 5,000 shares | -12% | |
| 31Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $410k 2,034 shares | -6% | |
| 20Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $94k 467 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.